Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo-7-[4-(1-Oxo-4-Phenoxybutyl)-1-Piperazinyl]- is a high-purity, advanced pharmaceutical intermediate of significant commercial importance. This compound is critical for the synthesis of next-generation fluoroquinolone antibiotics, offering a key structural moiety that influences potency and spectrum of activity. It is primarily required by research institutions and pharmaceutical manufacturers engaged in the development and production of novel antibacterial agents.

Application

• Pharmaceutical Intermediate: Serves as a crucial building block in the synthesis of novel fluoroquinolone antibiotic APIs (Active Pharmaceutical Ingredients).
• Antibacterial Drug Research: Used in R&D for developing new antibacterial compounds with improved efficacy against resistant strains.
• Chemical Synthesis: Employed in organic synthesis for constructing complex quinoline-based molecular architectures.
• Process Development: Utilized in scale-up and process optimization studies within pharmaceutical manufacturing.
• Reference Standard: Can serve as a high-purity analytical standard for quality control and regulatory submissions.

Basic Information

Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-4-Oxo-7-[4-(1-Oxo-4-Phenoxybutyl)-1-Piperazinyl]-
CAS No.	1053951-49-7
Molecular Formula	C27H28FN3O5
Molecular Weight	493.53 g/mol
Synonyms	1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-(1-oxo-4-phenoxybutyl)-1-piperazinyl]-3-quinolinecarboxylic acid; 7-[4-(4-Phenoxy-1-oxobutyl)-1-piperazinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid; WCK 771 Intermediate; Nalidixic Acid Derivative Intermediate; Advanced Fluoroquinolone Intermediate; 1-Cyclopropyl-6-fluoro-7-(4-(4-phenoxybutanoyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
EINECS	Contact for details

Quality Control

Our 3-Quinolinecarboxylic Acid derivative is manufactured under strict quality systems to ensure it meets the exacting standards required for pharmaceutical synthesis. Each batch undergoes comprehensive analytical testing, including HPLC for purity and identity confirmation via spectroscopic methods. Certificates of Analysis (COA) detailing all specifications and test results are provided and can be tailored to support regulatory filings (e.g., DMF, CMC sections).

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). This compound may be hygroscopic (moisture-sensitive); ensure the container is sealed under inert atmosphere if specified.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0% Any single impurity ≤0.5%
Water Content (KF)	≤0.5%
Residue on Ignition	≤0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.